Mechanism of Action
4 (PDE4) with at least nine-fold preferential inhibition of the PDE4B isoenzyme over PDE4A, PDE4C, and PDE4D based on in vitro data. PDE4 hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP). Nerandomilast exerts both antifibrotic and immunomodulatory effects as PDE4B inhibition…
Clinical Trials (5)
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood
A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Nerandomilast in the Blood